GlaxoSmithKline and Merck discontinue trials involving feladilimab

(Alliance News) - GlaxoSmithKline PLC late Wednesday said it has decided to stop enrolling ...

Alliance News 15 April, 2021 | 9:58AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GlaxoSmithKline PLC late Wednesday said it has decided to stop enrolling patients in the phase II Induce-3 trial, including discontinuing treatment with feladilimab.

The move follows a recommendation by the Independent Data Monitoring Committee. The Induce-3 study is investigating feladilimab in combination with pembrolizumab versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.

The Brentford, England-based Brentford said it also has decided to stop the Induce-4 phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.

The Induce-3 and Induce-4 studies are being conducted under an agreement between GSK and the US's Merck & Co Inc.

GSK shares were trading 1.5% lower in London on Thursday at 1,270.00 pence each. Merck & Co shares closed marginally lower in New York on Wednesday at USD76.40 each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,640.50 GBX 0.00
Merck & Co Inc 130.72 USD 2.93

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures